These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 31933265)

  • 1. Adverse Drug Reactions Involving Protein Kinase Inhibitors: A French Pharmacovigilance Database Study Comparing Safety in Younger and Older Patients (≥ 75 years) with Cancer.
    Clapes V; Rousseau V; Despas F; Montastruc JL; Olivier P
    Pharmaceut Med; 2019 Feb; 33(1):21-27. PubMed ID: 31933265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preventable and potentially preventable serious adverse reactions induced by oral protein kinase inhibitors through a database of adverse drug reaction reports.
    Egron A; Olivier-Abbal P; Gouraud A; Babai S; Combret S; Montastruc JL; Bondon-Guitton E
    Target Oncol; 2015 Jun; 10(2):229-34. PubMed ID: 25056801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of cellular targets involved in cardiac failure caused by PKI in oncology: an approach combining pharmacovigilance and pharmacodynamics.
    Patras de Campaigno E; Bondon-Guitton E; Laurent G; Montastruc F; Montastruc JL; Lapeyre-Mestre M; Despas F
    Br J Clin Pharmacol; 2017 Jul; 83(7):1544-1555. PubMed ID: 28098949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spontaneous reporting of serious cutaneous reactions with protein kinase inhibitors.
    Faye E; Bondon-Guitton E; Olivier-Abbal P; Montastruc JL;
    Eur J Clin Pharmacol; 2013 Oct; 69(10):1819-26. PubMed ID: 23748749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilance.
    Fornasier G; Taborelli M; Francescon S; Polesel J; Aliberti M; De Paoli P; Baldo P
    Int J Clin Pharm; 2018 Aug; 40(4):795-802. PubMed ID: 29785683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency and Nature of Adverse Drug Reactions Due to Non-Prescription Drugs in Children: A Retrospective Analysis from the French Pharmacovigilance Database.
    Durrieu G; Maupiler M; Rousseau V; Chebane L; Montastruc F; Bondon-Guitton E; Montastruc JL
    Paediatr Drugs; 2018 Feb; 20(1):81-87. PubMed ID: 28766184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Common causes and characteristics of adverse drug reactions in older adults: a retrospective study.
    Woo SD; Yoon J; Doo GE; Park Y; Lee Y; Lee SH; Lee YH; Ye YM
    BMC Pharmacol Toxicol; 2020 Dec; 21(1):87. PubMed ID: 33303036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab-induced serious side-effects: a review of the French pharmacovigilance database.
    Taugourdeau-Raymond S; Rouby F; Default A; Jean-Pastor MJ;
    Eur J Clin Pharmacol; 2012 Jul; 68(7):1103-7. PubMed ID: 22349162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse drug reactions in patients older than 70 years during the heat wave occurred in France in summer 2003: A study from the French PharmacoVigilance Database.
    Michenot F; Sommet A; Bagheri H; Lapeyre-Mestre M; Montastruc JL;
    Pharmacoepidemiol Drug Saf; 2006 Oct; 15(10):735-40. PubMed ID: 16924603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pleural adverse drugs reactions and protein kinase inhibitors: Identification of suspicious targets by disproportionality analysis from VigiBase.
    Mahé J; de Campaigno EP; Chené AL; Montastruc JL; Despas F; Jolliet P
    Br J Clin Pharmacol; 2018 Oct; 84(10):2373-2383. PubMed ID: 29943846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drugs and cancer: an analysis of the French Pharmacovigilance Database.
    Durrieu G; Mazau B; Jégu J; Lapeyre-Mestre M; Delord JP; Montastruc JL;
    Therapie; 2013; 68(3):149-54. PubMed ID: 23886459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulmonary arterial hypertension associated with protein kinase inhibitors: a pharmacovigilance-pharmacodynamic study.
    Cornet L; Khouri C; Roustit M; Guignabert C; Chaumais MC; Humbert M; Revol B; Despas F; Montani D; Cracowski JL
    Eur Respir J; 2019 May; 53(5):. PubMed ID: 30846469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative study of adverse drug reactions during two heat waves that occurred in France in 2003 and 2006.
    Sommet A; Durrieu G; Lapeyre-Mestre M; Montastruc JL;
    Pharmacoepidemiol Drug Saf; 2012 Mar; 21(3):285-8. PubMed ID: 22162094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proactive Regional Pharmacovigilance System Versus National Spontaneous Reporting for Collecting Safety Data on Concerning Off-Label Prescribing Practices: An Example with Baclofen and Alcohol Dependence in France.
    Auffret M; Labreuche J; Duhamel A; Deheul S; Cottencin O; Bordet R; Gautier S; Rolland B
    Drug Saf; 2017 Mar; 40(3):257-262. PubMed ID: 27988884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective analysis of reporting of adverse drug reactions to oncology drugs: An experience from a national center of clinical excellence.
    Sharma PK; Misra AK; Gupta A; Singh S; Dhamija P; Pareek P
    Indian J Pharmacol; 2018; 50(5):273-278. PubMed ID: 30636831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gender differences in adverse drug reactions: analysis of spontaneous reports to a Regional Pharmacovigilance Centre in France.
    Montastruc JL; Lapeyre-Mestre M; Bagheri H; Fooladi A
    Fundam Clin Pharmacol; 2002 Oct; 16(5):343-6. PubMed ID: 12608357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of acute kidney injury related to small-molecule protein kinase inhibitors using the FDA adverse event reporting system.
    Fan Q; Ma J; Zhang B; Li Q; Liu F; Zhao B
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):655-662. PubMed ID: 33001273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gadobutrol for contrast-enhanced magnetic resonance imaging in elderly patients: review of the safety profile from clinical trial, post-marketing surveillance, and pharmacovigilance data.
    Endrikat J; Schwenke C; Prince MR
    Clin Radiol; 2015 Jul; 70(7):743-51. PubMed ID: 25933719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of heart failure following exposure to a protein kinase inhibitor, a French population-based study.
    Zelmat Y; Conte C; Noize P; Vabre C; Pajiep M; Lafaurie M; Lapeyre-Mestre M; Despas F
    Br J Clin Pharmacol; 2023 Apr; 89(4):1338-1348. PubMed ID: 36285576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.